May 1, 2023

Updated IDFPR Statement on Recent Court Rulings About Mifepristone

On Friday, April 21, 2023, the United States Supreme Court stayed the Texas court ruling which had stayed the 2000 FDA approval of Mifepristone pending litigation on the merits. The U.S. Supreme Court ruling means that Mifepristone remains a legal reproductive healthcare option for women in Illinois, as well as across the nation. The Illinois Department of Financial and Professional Regulation (“IDFPR”) will not discipline physicians who prescribe or pharmacists who fulfill prescriptions of Mifepristone.

As a consumer protection regulatory agency, IDFPR will continue to uphold Illinois law protecting reproductive rights and ensuring that health care professionals maintain high quality standards in the provision of services. Illinois will continue to be a state that respects, values, and elevates an individual’s autonomy and welcomes individuals throughout the nation that need the provision of critical care services from our licensed professionals.